Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial

@article{Sandstrm1999TherapeuticIW,
  title={Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial},
  author={Eric Sandstr{\"o}m and Britta Wahren and Nordic VAC-04 Study Group},
  journal={The Lancet},
  year={1999},
  volume={353},
  pages={1735-1742}
}
BACKGROUND The immune system's ability to scavenge and destroy detrimental HIV-1 products has an important effect on virion production and the course of infection. In earlier trials of therapeutic immunisation with envelope protein recombinant gp160 (rgp160) we observed a transient positive effect on CD4-lymphocyte counts. This randomised placebo-controlled study investigated whether our preliminary findings represented a potential for a more benign clinical course. METHODS 835 HIV… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Similar Papers

Loading similar papers…